BHLHE40 and familial pancreatic carcinoma: Furthermore, CU-DREAMX analysis demonstrated that BHLHE40 and DDIT4 of PBMCs were not increased in patients with head and neck cancers and pancreatic cancer (Supplementary Fig. S4).